Therapeutic Resistance in G-CSF Producing Lung Cancer With EGFR Mutation

Koki Ito; Kyoichi Kaira; Hisao Imai; Ayako Shiono; Kosuke Hashimoto; O U Yamaguchi; Hiroshi Kagamu

doi:10.21873/cdp.10359

Therapeutic Resistance in G-CSF Producing Lung Cancer With EGFR Mutation

Cancer Diagn Progn. 2024 Jul 3;4(4):529-533. doi: 10.21873/cdp.10359. eCollection 2024 Jul-Aug.

Authors

Koki Ito¹, Kyoichi Kaira¹, Hisao Imai¹, Ayako Shiono¹, Kosuke Hashimoto¹, O U Yamaguchi¹, Hiroshi Kagamu¹

Affiliation

¹ Department of Respiratory Medicine, Comprehensive Cancer Center, International Medical Center, Saitama Medical University, Saitama, Japan.

Abstract

Background/aim: Granulocyte colony-stimulating factor (G-CSF)-producing neoplasms are relatively rare; however, little is known on the clinical features of G-CSF-producing lung cancer harboring activating epidermal growth factor receptor (EGFR) mutations.

Case report: A 66-year-old female was definitively diagnosed with G-CSF-producing lung cancer that was positive for EGFR mutations. She repeatedly received epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs), such as osimertinib and afatinib. However, she developed resistance to these molecular-targeting drugs within 2 to 3 months after immediate shrinkage. Thus, the patient was treated with chemoimmunotherapy including bevacizumab, and demonstrated a slight survival benefit.

Conclusion: Overall, G-CSF-producing lung cancers positive for EGFR mutations were resistant to different treatment modalities. Clinicians should be attentive to the potential resistance of G-CSF-producing EGFR mutant lung cancer to EGFR-TKI therapy.

Keywords: EGFR mutation; G-CSF; lung cancer.